Skip to content

Stroke Health Center

Font Size

New Anticlotting Drugs in the Works

Studies Show Apixaban and Xarelto Are Effective at Preventing Deadly Blood Clots
WebMD Health News
Reviewed by Laura J. Martin, MD

Sept. 1, 2010 (Stockholm, Sweden) -- Two experimental anticlotting drugs showed impressive results at preventing deadly blood clots, doctors say.

If approved, they will offer alternatives to the old standby, warfarin, which many people can't or won't take.

In one study of 5,600 patients who couldn't or wouldn't use warfarin, apixaban beat aspirin at preventing dangerous clots or strokes.

In the other study of more than 3,400 patients, the new pill Xarelto was as safe and effective as warfarin at dissolving potentially deadly blood clots in the legs and preventing new ones.

Both studies were presented at the European Society of Cardiology Congress.

Apixaban cut the risk of stroke by more than half compared with aspirin, says researcher Stuart Connolly, MD, of McMaster University in Hamilton, Ontario, Canada.

The rate of major bleeding, the key concern, was no higher among patients on apixaban, he says.

The late-stage phase III study was stopped early after apixaban's advantages became clear, Connolly tells WebMD.

Drawbacks of Warfarin

The study followed patients with atrial fibrillation (AF), a condition characterized by irregular heart rhythms. They're five times more likely to suffer a stroke than people without AF because their erratic heartbeats allow blood to pool in an upper chamber of the heart. Pooled blood is more likely to form clots, which can travel to the brain and block blood flow, causing a stroke.

Warfarin is the usual treatment, but up to half of patients can't take it because of increased bleeding risk or drug interactions, or refuse to take it. If too much is given, you can suffer a dangerous bleed; take too little, and you're at risk for a deadly blood clot related to the AF.

Aspirin is the usual care in patients who cannot take warfarin, but it's less effective. So there's a race on to find a better alternative, with apixaban, Xarelto, and a third drug, Pradaxa, leading the pack. Other anticlotting drugs in development include edoxaban and betrixaban.

Apixaban Study

In the new study, apixaban reduced the rate of strokes or major clots by 54%. The annual rate of strokes in patients on apixaban was 1.6% vs. 3.6% for those on aspirin, Connolly says.

1 | 2 | 3

Today on WebMD

brain illustration stroke
Know the 5 signs.
brain scans
Test your stroke smarts.
woman with migraine
Is there a link?
brain scan
Get the facts.
brain scans
woman with migraine
brain scan
quit smoking tips
Heart Foods Slideshow
Soy For High BP
BP Medicine
Lowering Cholesterol Slideshow

WebMD Special Sections